Background: Cognitive deficit associated with cancer and its treatment is called cancer-related cognitive impairment (CRCI). Increases in cancer survival have made understanding the basis of CRCI more important. CRCI neuroimaging studies have traditionally used dedicated research brain MRIs in breast cancer survivors after chemotherapy with small sample sizes; little is known about other non-central nervous system (CNS) cancers after chemotherapy as well as those not exposed to chemotherapy. However, there may be a wealth of unused data from clinically-indicated MRIs that could be used to study CRCI. Objective: Evaluate brain cortical structural differences in those with various non-CNS cancers using clinicallyindicated MRIs. Design: Cross-sectional Patients: Adult non-CNS cancer and non-cancer control (C) patients who underwent clinically-indicated MRIs. Methods: Brain cortical surface area and thickness were measured using 3D T1-weighted images. An age-adjusted linear regression model was used and the Benjamini and Hochberg false discovery rate (FDR) corrected for multiple comparisons. Group comparisons were: cancer cases with chemotherapy (Ch+), cancer cases without chemotherapy (Ch-) and subgroup of lung cancer cases with and without chemotherapy vs C. Results: Sixty-four subjects were analyzed: 22 Ch+, 23 Ch-and 19 C patients. Subgroup analysis of 16 lung cancer (LCa) patients was also performed. Statistically significant decreases in either cortical surface area or thickness were found in multiple regions of interest (ROIs) primarily within the frontal and temporal lobes for all comparisons. Effect sizes were variable with the greatest seen in the left middle temporal surface area ROI (Cohen's d -0.690) in the Ch-vs C group comparison. Limitations: Several limitations were apparent including a small sample size that precluded adjustment for other covariates. Conclusions: Our preliminary results suggest that, in addition to breast cancer, other types of non-CNS cancers treated with chemotherapy may result in brain structural abnormalities. Similar findings also appear to occur in those not exposed to chemotherapy. These results also suggest that there is potentially a wealth of untapped clinical MRIs that could be used for future CRCI studies.
INTRODUCTION
Cancer is a major public health problem and the second leading cause of death in the United States [1] . Fortunately, advances in non-central nervous system (CNS) cancer diagnosis and therapy have resulted in greater numbers of cancer survivors [2] [3] [4] . Given these statistics, increasing attention has been focused on the morbidity associated with cancer survival, including the cognitive deficits secondary to cancer and its treatment. This has been referred to as cancerrelated cognitive impairment (CRCI) [2] and "chemobrain," CRCI thought to be due to chemotherapy, may affect up to 78% of cancer survivors [5] and can adversely affect survivors' quality-of-life. Cognitive deficits associated with chemobrain usually manifest as loss of episodic and working memory, slower processing speed and executive dysfunction. The degree of dysfunction is often mild to modest and it can be chronic in up to 35% of patients [6, 7] .
The underlying biological mechanisms and neural substrates affected in patients with CRCI have recently become a focus of intense study. Several theories about how chemotherapeutic agents cause cognitive dysfunction include, but are not limited to, injury to neural progenitor cells and postmitotic oligodendrocytes [8, 9] , oxidative injury [10] , reduced neurogenesis and white matter integrity [8, 11] . With regard to how cancer itself could result in CRCI, several mechanisms have been proposed including inflammation and inadequate DNA repair mechanisms [2] .
Neuroimaging is a powerful method to study the neuroanatomical alterations associated with CRCI. So far, most of what is known comes from MRI studies of breast cancer survivors after chemotherapy [4, 12] generally using a crosssectional design with small sample sizes. Structural T1-weighted, diffusion tensor imaging (DTI) and functional MRI (fMRI) studies suggest that there are significant anatomical and functional differences between breast cancer survivors and healthy controls [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] ; comparatively little work has focused on breast cancer survivors who have not been exposed to chemotherapy. Furthermore, little is known about cancers outside of the breast, but recent publications using structural and functional MRI (fMRI) focusing on other types of cancers [26] [27] [28] [29] also suggest that significant brain differences exist between these cancer patients and controls.
Additionally, CRCI MRI studies have generally used research-dedicated brain scans. Like many other biomedical fields, it is becoming more and more critical to show reproducible effects across large, well-powered cohorts. Interestingly, there may be a large body of untapped brain MRI data performed for clinical purposes which could help to address many unanswered questions regarding CRCI. We hypothesize that there are statistically significant differences in cortical structures among patients with various non-CNS cancers treated with and without chemotherapy compared to non-cancer controls. The primary objective of this cross-sectional pilot study was to test this hypothesis in a cohort of patients with different types of non-CNS cancers. Rather than using research-dedicated scans, we used already-existing clinical MRI scans that were intended to exclude brain metastatic disease.
METHODOLOGY

Study Design and Setting:
This was a HIPAA-compliant, single-institution, IRB-approved, retrospective crosssectional pilot study performed at the Keck Hospital of the University of Southern California (USC). A waiver of informed consent was obtained.
Participants:
Our inclusion criteria included adults ≥ 18 years of age with various non-CNS cancers (cases) and those without cancer (controls) who underwent brain MRI that included volumetric non-contrast-enhanced T1-weighted imaging from January 2016 to June 2017. Subjects were found using the Montage neuroimaging database. Cases were scanned to exclude brain metastases and controls to evaluate a variety of clinical indications including headache, dizziness or vertigo, among others. Exclusion criteria included patients with histories of intrathecal or intraventricular chemotherapy, cranial radiation, metastatic brain tumors and documented neuropsychiatric disorders including histories of migraine, depression, anxiety and other neuropsychiatric conditions.
Variables and Image Processing:
For each subject, structural T1-weighted magnetic resonance imaging (MRI) brain scans were performed on one of three 3T MRI scanners. Images were analyzed using the open-source, fully automated and validated segmentation software FreeSurfer version 5.3 [30] . Image acquisition parameters are given in Table 1 . The segmentations of 141 regions were extracted, including the lateral ventricles and total ICV. Average values of bilateral regions were also calculated. All segmentations were visually inspected for accuracy by (FR, 2 years of experience) following a thorough and standardized quality control protocol designed by the ENIGMA Consortium (http:// enigma.ini.usc.edu/protocols/imaging-protocols/). Each image segmentation was also independently verified by a neuroimaging expert (MSS, 7 years of experience) at each site by overlaying the segmentation label of each structure on the T1-weighted brain scan.
Data Sources:
All clinical characteristics were obtained through a search of the electronic medical record.
Study Size:
As this was a pilot study, formal sample size calculations were not performed.
Statistical Methods:
Data for all regions of interest (ROIs) were corrected by the intracranial volume (ICV) by using the percent of ICV. Histograms and the D'Agostino's K-squared test were used to determine the distribution of the data. For data not normally distributed, a Wilcoxon score transformation was used so that the comparison was conducted in a non-parametric fashion. We utilized an age-adjusted linear regression model and the residuals after age adjustment were used for the group comparisons. Independent t-tests were used for group comparisons using data with a normal distribution. Wilcoxon Rank Sum tests were used when the data distribution was not normal. The Benjamini and Hochberg false discovery rate (FDR) was used for multiple comparisons correction to control the false positive rate at 5%. Effect sizes (Cohen's d) were also determined. SAS 9.4 was used for the statistical analysis. The following group comparisons were made: cancer cases treated with chemotherapy (Ch+) vs control (C); cancer cases without chemotherapy (Ch-) vs C; subgroup analysis of lung cancer cases with and without chemotherapy (LCa) was also compared vs C.
RESULTS
Participants:
A total of 64 subjects were ultimately included in our analysis. There were 45 case and 19 C patients. Of the cancer cases, 22 were scanned after chemotherapy (Ch+) while 23 were scanned without chemotherapy (Ch-). Please refer to the flow diagram ( Figure 1 ) for further details. The most common cancer in our cohort was lung cancer (n = 16). Six cancer cases had developed 2 different types of cancers. Clinical characteristics of our entire cohort are listed in Table 2. Table 3 depicts the different chemotherapy drugs that were used in our Ch+ cohort.
Main Results:
Our analysis detected statistically significant decrease in either cortical surface area or cortical thickness in ROIs of primarily the frontal and temporal lobes for the comparisons between Ch+ vs. C, Ch-vs. C, and LCa vs. C. An overview of these ROIs is listed in Table 4 . Effect sizes were variable with the greatest seen in the left middle temporal surface area ROI (Cohen's d -0.690, 95% confidence interval (-1.329, -0.051)) in the Ch-vs C group comparison.
DISCUSSION
Cancer survivors make up an ever-increasing proportion of the public. There were an estimated 15.5 million cancer survivors in the US as of January 2016 and this is projected to increase to 26.1 million survivors by 2040 [31] . Given these statistics, it is critical to better understand the biological mechanisms and neuroanatomical substrates that underlie CRCI. In contrast to prior CRCI-related neuroimaging studies which have generally used dedicated research imaging scans, we used clinical brain MRI data collected to assess for possible CNS metastases of multiple types of primary non-CNS cancers.
Both the neuroimaging [4, 12] and neuropsychological literature [2] generally support the notion of the existence of structural/functional neuroimaging abnormalities and cognitive dysfunction due to cancer and chemotherapy. However, much of this evidence should still be considered preliminary due to the lack of data available outside of breast cancer, preponderance of cross-sectional designs with small sample sizes and a paucity of well-powered prospective, longitudinal cohort studies [2] .
Our results have shown that, compared to non-cancer controls, those with a various non-CNS cancers have statistically significant decreases in either cortical surface area or cortical thickness, primarily affecting the frontal and temporal lobes. This difference was present in both Ch+ and Ch-groups. Furthermore, subgroup analysis of the LCa group showed similar differences. These findings are consistent with the prior work where the majority of structural T1-weighted CRCI neuroimaging studies after chemotherapy have been performed using breast cancer patients. Overall, these studies have found reductions of GM and WM throughout the brain [13] [14] [15] [16] [17] [18] [19] , and when the findings have been focal, involvement of the frontotemporal regions is common [12] . Some of these structural abnormalities [16, 19, 32, 33] have also been associated with cognitive deficits. This appears to reflect the notion that cancer and chemotherapy are more prone to injure the frontotemporal regions that are critical to cognitive functions like episodic memory and executive function [12] Other structural MRI studies from DTI [20] [21] [22] as well as fMRI studies [23] [24] [25] have also provided complementary evidence documenting abnormal WM integrity and brain activation patterns due to breast cancer and chemotherapy.
The findings from our Ch-cohort are also in agreement with the few neuroimaging studies that have studied cancer patients not exposed to chemotherapy. Structural [15, 19, 34] and functional MRI [23, 24, 35] studies have found that abnormalities may already exist in the absence of chemotherapy for breast cancer patients. More recent neuroimaging studies of other types of cancer including lung [26] and testicular cancer [27] also suggest that structural abnormalities exist without chemotherapy. This is further supported by neuropsychological data in breast [36, 37] , testicular [27] and lung cancer [26] patients not treated with chemotherapy.
Little is known whether neuroimaging changes are also present in individuals with other types of non-CNS cancers outside of the breast. Our overall findings that also included subgroup analysis of our LCa cohort are in line with a recent cross sectional MRI study of lung cancer [26] . In this study, cognitive dysfunction and diffuse WM abnormalities from DTI were present prior to chemotherapy. In addition, cognitive dysfunction, GM reduction in the left anterior cingulate cortex and the bilateral parahippocampal gyri and insula, as well as focally decrease WM integrity in bilateral inferior longitudinal fasciculi and left cingulum were found in chemotherapy-exposed subjects compared to healthy controls. A few other recent publications of structural MRI of testicular cancer [27] as well as fMRI studies of prostate [28] and various cancers [29] , including breast, colorectal, Hodgkin's lymphoma, leukemia and myeloma, similarly support the presence of structural/functional neuroimaging and cognitive abnormalities in these malignancies following treatment.
Several limitations should be kept in mind when interpreting the findings of this study. First, the cross-sectional design makes it difficult to establish whether structural brain alterations developed after cancer and chemotherapy. Second, we used a sample of convenience given the retrospective nature of the study. In addition, the cancer cases in this cohort were compared to what was readily available on the same MRI scanners, a non-cancer control group, rather than a healthy control group. Third, there was a heterogeneous mixture of non-CNS cancer types and treatment regimens. Fourth, the relatively small sample size precluded adjustment for other covariates that could impact the results. Fifth, both the cancer cases and non-cancer controls were scanned for clinical indications, and could differ from cancer survivors in general as well as healthy controls. Lastly, our method of surface-based image processing with FreeSurfer differed from most other structural MRI studies of CRCI which have largely relied on voxel-based morphometry (VBM) [4, 12] .
CONCLUSIONS
While considering these limitations, these preliminary results support the notion that non-CNS cancers other than breast cancer treated with chemotherapy may be associated with brain structural abnormalities. Similar findings also appear to exist in these cancer patients even in the absence of chemotherapy. These findings should be validated in larger studies, ideally with a prospective, longitudinal cohort design focusing on a wide variety of cancers. Furthermore, while CRCI brain MRI studies have generally used research-dedicated scans, our results suggest that there is a wealth of untapped neuroimaging data obtained for clinical indications that could form the basis of future CRCI neuroimaging studies. 
